Using the AUA Measurement Committee's BPH impact index assessment...
FLOMAX significantly improved quality of life (QOL) during the first year of treatment, and the improvement was maintained for up to 6 years1
- For each year, a statistically significant improvement from baseline was recorded
- The percentage of patients responding to treatment (defined as ≥30% change from baseline) was greatest during the first year and was maintained throughout the duration of the study Learn more about this trial
FLOMAX relieves both the obstructive and irritative symptoms of BPH2,3
- Obstructive: incomplete emptying, intermittency, weak stream, straining
- Irritative: nocturia, frequency, urgency
See data from FLOMAX clinical trials
| Learn more about the trusted safety of FLOMAX |
Important Safety Information
FLOMAX is indicated to treat the signs and symptoms of benign prostatic hyperplasia (BPH). FLOMAX is not indicated to treat hypertension. As with other alpha-adrenergic blocking agents, there is a potential risk of syncope. Patients beginning treatment with FLOMAX should be cautioned to avoid situations where injury could result should syncope occur. The most common side effects are dizziness, abnormal ejaculation, and rhinitis.
Caution should be exercised with concomitant administration of warfarin and FLOMAX. In addition, FLOMAX should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. FLOMAX is contraindicated in patients known to be hypersensitive to tamsulosin HCl or any component of FLOMAX.
Before prescribing FLOMAX, please see the full Prescribing Information.
1 Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170:498-502.
2 Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
3 American Urological Association. Guideline on the Management of Benign Prostatic Hyperplasia (BPH). Linthicum, Md: American Urological Association Education and Research, Inc; 2003:1-22,1-23,3-51.
